Immune checkpoint inhibitor (ICI) therapy has revolutionized the management of various
cancers with previously poor prognosis. Despite its great efficacy, the therapy is associated …

Neuromuscular adverse events following cancer treatment with anti-programmed cell death
protein 1 (PD-1) monoclonal antibodies are relatively rare, yet potentially fatal. We …

Background Rheumatic and musculoskeletal immune-related adverse events (irAEs) are
observed in about 10% of patients with cancer receiving checkpoint inhibitors (CPIs). Given …

Aim To characterise clinical presentation, laboratory and histopathologic characteristics and
assess the treatment and outcome of neuromuscular side-effects of checkpoint therapy …

Abstract Programmed death-1 (PD-1) inhibitors are increasingly used in cancer
immunotherapy. Various immune-related adverse events are reported, including infrequent …

The development of immune checkpoint inhibitors (ICIs) has been a major breakthrough in
cancer immunotherapy. The increasing use of ICIs has led to the discovery of a broad …

Abstract Purpose of Review In recent years, immune checkpoint inhibitors have been
increasingly used in patients with metastatic cancers with favorable oncological outcomes; …

Immune checkpoint inhibitors have revolutionized the landscape of cancer treatment.
Alongside their many advantages, they elicit immune-related adverse events, including …

Immune checkpoint inhibitor (ICI)-related myositis is a rare, potentially fatal condition that
warrants further studies. Its incidence, clinical features, and prognosis remain poorly …

Background: Immune checkpoint inhibitors are a new promising class of antitumor drugs that
have been associated with a number of immune-related Adverse Events (AEs), including …